Free Trial

Neurogene (NGNE) Competitors

Neurogene logo
$20.05 +0.30 (+1.49%)
Closing price 03:54 PM Eastern
Extended Trading
$20.00 -0.05 (-0.25%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NGNE vs. WVE, VERV, PAHC, AKBA, COLL, NTLA, PHVS, CRMD, RCUS, and SYRE

Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include WAVE Life Sciences (WVE), Verve Therapeutics (VERV), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Pharvaris (PHVS), CorMedix (CRMD), Arcus Biosciences (RCUS), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

Neurogene vs. Its Competitors

WAVE Life Sciences (NASDAQ:WVE) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 29.1% of WAVE Life Sciences shares are held by insiders. Comparatively, 11.6% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Neurogene had 7 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Neurogene and 0 mentions for WAVE Life Sciences. Neurogene's average media sentiment score of 0.15 beat WAVE Life Sciences' score of 0.00 indicating that Neurogene is being referred to more favorably in the news media.

Company Overall Sentiment
WAVE Life Sciences Neutral
Neurogene Neutral

Neurogene's return on equity of -36.16% beat WAVE Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
WAVE Life SciencesN/A -86.49% -37.20%
Neurogene N/A -36.16%-32.51%

WAVE Life Sciences presently has a consensus price target of $20.50, suggesting a potential upside of 194.12%. Neurogene has a consensus price target of $46.17, suggesting a potential upside of 130.32%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Neurogene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.92
Neurogene
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

WAVE Life Sciences has a beta of -1.01, indicating that its stock price is 201% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Neurogene has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WAVE Life Sciences$108.30M10.01-$97.01M-$0.84-8.30
Neurogene$930K307.36-$75.14M-$4.35-4.61

Summary

Neurogene beats WAVE Life Sciences on 8 of the 15 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NGNE vs. The Competition

MetricNeurogeneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$285.84M$2.89B$5.49B$9.01B
Dividend YieldN/A2.64%5.39%4.09%
P/E Ratio-4.6121.5627.4320.06
Price / Sales307.36281.29398.25108.31
Price / CashN/A41.4736.1356.90
Price / Book0.967.518.085.67
Net Income-$75.14M-$55.05M$3.16B$248.47M
7 Day Performance20.97%3.16%2.12%2.90%
1 Month Performance-2.50%5.92%4.43%5.75%
1 Year Performance-44.29%5.82%35.62%21.36%

Neurogene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NGNE
Neurogene
3.8165 of 5 stars
$20.05
+1.5%
$46.17
+130.3%
-48.6%$285.84M$930K-4.6190News Coverage
WVE
WAVE Life Sciences
4.1595 of 5 stars
$6.96
+5.9%
$20.50
+194.5%
+29.3%$1.01B$108.30M-8.29240
VERV
Verve Therapeutics
3.318 of 5 stars
$11.11
+0.5%
$14.75
+32.8%
+124.2%$985.92M$32.33M-5.27110High Trading Volume
PAHC
Phibro Animal Health
3.5731 of 5 stars
$24.46
+2.4%
$20.80
-15.0%
+67.3%$967.94M$1.02B31.361,940
AKBA
Akebia Therapeutics
4.3589 of 5 stars
$3.64
-1.1%
$6.75
+85.4%
+278.1%$966.50M$160.18M-17.33430Positive News
Insider Trade
COLL
Collegium Pharmaceutical
4.0327 of 5 stars
$29.88
+0.2%
$43.75
+46.4%
-4.8%$958.49M$631.45M24.49210
NTLA
Intellia Therapeutics
4.6488 of 5 stars
$9.23
+0.3%
$34.95
+278.7%
-51.6%$952.96M$57.88M-1.76600
PHVS
Pharvaris
1.4724 of 5 stars
$17.42
-3.2%
$36.20
+107.8%
+5.8%$940.70MN/A-5.7930Gap Up
CRMD
CorMedix
2.4257 of 5 stars
$16.56
+21.7%
$15.83
-4.4%
+181.3%$923.09M$43.47M75.2830Analyst Forecast
Analyst Revision
High Trading Volume
RCUS
Arcus Biosciences
2.8801 of 5 stars
$8.65
+0.3%
$24.13
+179.1%
-41.4%$912.73M$258M-2.06500
SYRE
Spyre Therapeutics
1.5793 of 5 stars
$14.68
-2.2%
$53.40
+263.8%
-34.8%$904.74M$890K-3.8973

Related Companies and Tools


This page (NASDAQ:NGNE) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners